Drug Trial Radar · NCT06624228
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
553
Actual
Start
Oct 21, 2024
Primary completion
Feb 6, 2026
Study completion Jun 3, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Conditions
- Psoriatic Arthritis
Interventions
BimekizumabDrug
Study participants will receive bimekizumab at pre-specified time points.
RisankizumabDrug
Study participants will receive risankizumab at pre-specified time points.
PlaceboDrug
Study participants will receive placebo at pre-specified time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology 50 (ACR50) at Week 16Time frame: Week 16
Locations
127 sites in 11 countries. Site status is shown where the registry gives one.
Pa0016 50662
Gilbert, Arizona
Pa0016 50062
Glendale, Arizona
Pa0016 50058
Phoenix, Arizona
Pa0016 50131
Sun City, Arizona
Pa0016 50654
Covina, California
Pa0016 50663
San Diego, California
Pa0016 50672
Santa Monica, California
Pa0016 50630
Clearwater, Florida
Pa0016 50679
Cutler Bay, Florida
Pa0016 50685
Fort Lauderdale, Florida
Pa0016 50059
Ormond Beach, Florida
Pa0016 50324
Plantation, Florida
Pa0016 50678
Zephyrhills, Florida
Pa0016 50651
Skokie, Illinois
Pa0016 50650
Willowbrook, Illinois
Pa0016 50686
Hagerstown, Maryland
Pa0016 50665
Lansing, Michigan
Pa0016 50551
Saint Clair Shores, Michigan
Pa0016 50689
Eagan, Minnesota
Pa0016 50682
Kansas City, Missouri
Pa0016 50016
St Louis, Missouri
Pa0016 50653
Albuquerque, New Mexico
Pa0016 50666
Brooklyn, New York
Pa0016 50664
Middletown, Ohio
Pa0016 50680
Vandalia, Ohio
Pa0016 50652
Duncansville, Pennsylvania
Pa0016 50006
Wyomissing, Pennsylvania
Pa0016 50001
Jackson, Tennessee
Pa0016 50673
Fort Worth, Texas
Pa0016 50048
Katy, Texas
Pa0016 50657
Lubbock, Texas
Pa0016 50655
Tomball, Texas
Pa0016 50061
Spokane Valley, Washington
Pa0016 50674
Glendale, Wisconsin
Pa0016 30002
Clayton, Australia
Pa0016 30034
Footscray, Australia
Pa0016 30033
Heidelberg, Australia
Pa0016 30003
Maroochydore, Australia
Pa0016 30032
Parramatta, Australia
Pa0016 30009
Westmead, Australia
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.